Advertisement
EDIT vs NKTX
Which Stock Would AI Choose? Editas Medicine (EDIT) vs. Nkarta (NKTX) Stock Comparison
Key Takeaways
- Two distinct biotech plays: EDIT is a preclinical CRISPR gene-editing company, while NKTX is a clinical-stage CAR-NK cell therapy developer targeting autoimmune disease.
- Different development stages: NKTX is advancing a Phase 1 program with near-term data catalysts, while EDIT has pivoted back to preclinical development following a late-2024 restructuring.
- Cash positioning favors durability: Both companies hold multi-year runways, but NKTX's cash balance and runway relative to its clinical progress stand out.
- Analyst sentiment diverges: NKTX carries a Strong Buy consensus with substantial upside targets, whereas EDIT holds a more mixed "Moderate Buy/Hold" profile.
- Tickeron AI Verdict: Based on trend consistency, catalyst timing, and relative market positioning, Tickeron's AI currently favors NKTX over EDIT.
- Explore more on each name via EDIT Major News and EDIT Today's Price Move, as well as NKTX Major News and NKTX Today's Price Move.
- For a broader view of AI-driven strategies across the market, explore Trending AI Robots.
Introduction
Biotechnology investors often weigh companies at very different points in the drug-development lifecycle, and this stock comparison between EDIT and NKTX illustrates that tension clearly. Editas Medicine (EDIT) is a pioneer in CRISPR gene editing that has recently refocused on early-stage, in vivo (inside-the-body) programs. Nkarta (NKTX) is an engineered natural killer (NK) cell therapy company now concentrating on autoimmune diseases. Both are pre-revenue, cash-burning clinical biotechs, yet their risk profiles, catalyst calendars, and market positioning differ meaningfully. This comparison is most relevant for growth-oriented and event-driven traders and investors who track clinical milestones, financing activity, and relative performance within the volatile small-cap biotech sector.
EDIT Overview and Recent Performance
Editas Medicine is a Cambridge, Massachusetts-based genome editing company built on CRISPR/Cas9 and Cas12a technologies. Following the December 2024 decision to discontinue its reni-cel sickle cell program and cut roughly 65% of its workforce, the company returned to a preclinical stage and refocused its pipeline on in vivo gene editing. Its lead candidate, EDIT-401, is a one-time therapy designed to durably lower LDL cholesterol ("bad" cholesterol) in patients with heterozygous familial hypercholesterolemia (a genetic condition causing very high cholesterol).
In recent market activity, EDIT has shown volatile but generally recovering price behavior. The company reported a narrower-than-expected third-quarter loss and stronger revenue, while also completing a public offering in recent months to bolster its balance sheet. Management has indicated its cash position should fund operations into 2028. Sentiment has been shaped by preclinical data updates for EDIT-401, the capital raise, and a broader pivot narrative as the company rebuilds toward first-in-human studies. The absence of an approved product and a relatively long timeline to clinical proof-of-concept remain central investor considerations.
NKTX Overview and Recent Performance
Nkarta is a clinical-stage biopharmaceutical company based in South San Francisco developing allogeneic, "off-the-shelf" engineered natural killer (NK) cell therapies. Its lead candidate, NKX019, is a CD19-directed CAR-NK (chimeric antigen receptor-natural killer) therapy being evaluated in Phase 1 studies for multiple autoimmune diseases, including lupus nephritis, systemic sclerosis, and inflammatory myopathies.
In recent weeks, NKTX has drawn attention for a regulatory agreement with the FDA enabling outpatient dosing and re-dosing, along with an expansion of its Ntrust-2 study to include rheumatoid arthritis. The company has also reported initial clinical data for NKX019 in autoimmune disease at a major rheumatology conference, a key near-term catalyst. Financially, NKTX ended recent quarters with a cash balance sufficient to fund operations for several years, and its third-quarter loss came in modestly wider than consensus. Analyst coverage leans strongly bullish, with a "Strong Buy" consensus and price targets well above the current share price, reflecting optimism around the autoimmune pivot and upcoming data readouts.
Trending AI Robots
Tickeron maintains a broad library of hundreds of AI trading bots that collectively trade thousands of different tickers, each with its own trading style, strategy, timeframe, performance statistics, and watchlist of securities. Because not every bot suits every market environment, Tickeron curates a smaller, focused selection of the most promising strategies into its Trending AI Robots page. This section highlights the bots best aligned with current market conditions, helping traders and investors review algorithmic approaches without manually sifting through the entire catalog. For those interested in systematic, data-driven market analysis alongside their own research, exploring the Trending AI Robots page can offer a useful starting point.
Head-to-Head Comparison
Across key dimensions, EDIT and NKTX present contrasting trade-offs. In business model, EDIT is a platform-driven gene editing company pivoting toward large cardiovascular indications, while NKTX is a cell therapy company targeting autoimmune diseases. Their growth drivers also differ: EDIT's value rests on preclinical validation and eventual first-in-human data for EDIT-401, whereas NKTX's hinges on near-term Phase 1 readouts and regulatory flexibility that could broaden its addressable market.
On recent momentum, both stocks have recovered off 52-week lows, but NKTX's gains have been reinforced by tangible clinical and regulatory milestones, while EDIT's strength has been driven more by cost discipline, financing, and preclinical progress. Risk factors overlap significantly—both names face clinical uncertainty, dilution, and binary data events—but EDIT carries the additional risk of a longer runway to any pivotal catalyst. In market sentiment, analyst consensus and price targets currently lean more favorably toward NKTX, reflecting greater confidence in its nearer-term clinical story.
Tickeron AI Verdict
Weighing observable factors such as trend consistency, catalyst proximity, balance-sheet durability, and relative positioning, Tickeron's AI currently appears to favor NKTX over EDIT. NKTX benefits from a defined clinical-stage pipeline with near-term data catalysts, a favorable regulatory agreement, and a stronger analyst consensus, which together suggest a more stable and catalyst-rich setup. EDIT, by contrast, remains a longer-horizon preclinical story with substantial promise but greater distance from proof-of-concept. This assessment is probabilistic rather than definitive, reflecting the inherent uncertainty in early-stage biotechnology rather than a recommendation to buy or sell either security.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is EDIT is a StrongBuy and NKTX is a StrongBuy.
Aroon Indicator for EDIT shows an upward move is likely
EDIT's Aroon Indicator triggered a bullish signal on November 11, 2026. Tickeron's A.I.dvisor detected that the AroonUp green line is above 70 while the AroonDown red line is below 30. When the up indicator moves above 70 and the down indicator remains below 30, it is a sign that the stock could be setting up for a bullish move. Traders may want to buy the stock or look to buy calls options. A.I.dvisor looked at 154 similar instances where the Aroon Indicator showed a similar pattern. In 128 of the 154 cases, the stock moved higher in the days that followed. This puts the odds of a move higher at 83%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The Stochastic Oscillator is in the oversold zone. Keep an eye out for a move up in the foreseeable future.
Following a +7.84% 3-day Advance, the price is estimated to grow further. Considering data from situations where EDIT advanced for three days, in 182 of 227 cases, the price rose further within the following month. The odds of a continued upward trend are 80%.
Bearish Trend Analysis
The Momentum Indicator moved below the 0 level on November 10, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on EDIT as a result. In 78 of 84 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 90%.
The Moving Average Convergence Divergence Histogram (MACD) for EDIT turned negative on November 11, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 49 similar instances when the indicator turned negative. In 44 of the 49 cases the stock turned lower in the days that followed. This puts the odds of success at 90%.
EDIT moved below its 50-day moving average on November 10, 2026 date and that indicates a change from an upward trend to a downward trend.
The 50-day moving average for EDIT moved below the 200-day moving average on November 09, 2026. This could be a long-term bearish signal for the stock as the stock shifts to an downward trend.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where EDIT declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 90%.
EDIT broke above its upper Bollinger Band on October 28, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
Fundamental Analysis (Ratings)
The Tickeron PE Growth Rating for this company is 30 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Valuation Rating of 53 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (3.749) is normal, around the industry mean (3.498). P/E Ratio (-3.894) is within average values for comparable stocks, (-1.193). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (130.981) among similar stocks. P/S Ratio (5.855) is also within normal values, averaging (440.869).
The Tickeron Price Growth Rating for this company is 71 (best 1 - 100 worst), indicating slightly worse than average price growth. EDIT’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 99 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. EDIT’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 93, placing this stock worse than average.
NKTX sees its 50-day moving average cross bearishly below its 200-day moving average
The 50-day moving average for NKTX moved below the 200-day moving average on October 21, 2026. This could be a long-term bearish signal for the stock as the stock shifts to an downward trend.
Technical Analysis (Indicators)
Bearish Trend Analysis
The 10-day moving average for NKTX crossed bearishly below the 50-day moving average on October 07, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In 12 of 14 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are 86%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where NKTX declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 89%.
The Aroon Indicator for NKTX entered a downward trend on November 11, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Bullish Trend Analysis
The RSI Indicator points to a transition from a downward trend to an upward trend -- in cases where NKTX's RSI Oscillator exited the oversold zone, 39 of 41 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 90%.
The Stochastic Oscillator suggests the stock price trend may be in a reversal from a downward trend to an upward trend. 52 of 66 cases where NKTX's Stochastic Oscillator exited the oversold zone resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 79%.
The Moving Average Convergence Divergence (MACD) for NKTX just turned positive on November 04, 2026. Looking at past instances where NKTX's MACD turned positive, the stock continued to rise in 34 of 46 cases over the following month. The odds of a continued upward trend are 74%.
Following a +13.82% 3-day Advance, the price is estimated to grow further. Considering data from situations where NKTX advanced for three days, in 208 of 247 cases, the price rose further within the following month. The odds of a continued upward trend are 84%.
NKTX may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
Fundamental Analysis (Ratings)
The Tickeron PE Growth Rating for this company is 14 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Valuation Rating of 37 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (0.500) is normal, around the industry mean (3.498). P/E Ratio (-1.088) is within average values for comparable stocks, (-1.193). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (130.981) among similar stocks. P/S Ratio (0.000) is also within normal values, averaging (440.869).
The Tickeron Price Growth Rating for this company is 88 (best 1 - 100 worst), indicating slightly worse than average price growth. NKTX’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 97 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. NKTX’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 93, placing this stock worse than average.
EDIT | NKTX | ||
|---|---|---|---|
OUTLOOK RATING 1..100 | 73 | 4 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 53 Fair valued | 37 Fair valued | |
PROFIT vs RISK RATING 1..100 | 100 | 100 | |
SMR RATING 1..100 | 99 | 97 | |
PRICE GROWTH RATING 1..100 | 71 | 88 | |
P/E GROWTH RATING 1..100 | 30 | 14 | |
SEASONALITY SCORE 1..100 | 85 | 50 |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
NKTX's Valuation (37) in the null industry is in the same range as EDIT (53) in the Biotechnology industry. This means that NKTX’s stock grew similarly to EDIT’s over the last 12 months.
NKTX's Profit vs Risk Rating (100) in the null industry is in the same range as EDIT (100) in the Biotechnology industry. This means that NKTX’s stock grew similarly to EDIT’s over the last 12 months.
NKTX's SMR Rating (97) in the null industry is in the same range as EDIT (99) in the Biotechnology industry. This means that NKTX’s stock grew similarly to EDIT’s over the last 12 months.
EDIT's Price Growth Rating (71) in the Biotechnology industry is in the same range as NKTX (88) in the null industry. This means that EDIT’s stock grew similarly to NKTX’s over the last 12 months.
NKTX's P/E Growth Rating (14) in the null industry is in the same range as EDIT (30) in the Biotechnology industry. This means that NKTX’s stock grew similarly to EDIT’s over the last 12 months.
| EDIT | NKTX | |
|---|---|---|
| RSI ODDS (%) | N/A | 1 day ago 90% |
| Stochastic ODDS (%) | 1 day ago 77% | 1 day ago 79% |
| Momentum ODDS (%) | 1 day ago 90% | N/A |
| MACD ODDS (%) | 1 day ago 90% | 1 day ago 74% |
| TrendWeek ODDS (%) | 1 day ago 90% | 1 day ago 87% |
| TrendMonth ODDS (%) | 1 day ago 89% | 1 day ago 87% |
| Advances ODDS (%) | 3 days ago 80% | 8 days ago 84% |
| Declines ODDS (%) | 1 day ago 90% | 2 days ago 89% |
| BollingerBands ODDS (%) | 1 day ago 90% | 1 day ago 83% |
| Aroon ODDS (%) | 1 day ago 83% | 1 day ago 85% |
Long-Term Analysis
It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is overvalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
EDIT’s FA Score shows that 1 FA rating(s) are green while NKTX’s FA Score has 1 green FA rating(s).
- EDIT’s FA Score: 1 green, 4 red.
- NKTX’s FA Score: 1 green, 4 red.
Short-Term Analysis
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
EDIT’s TA Score shows that 3 TA indicator(s) are bullish while NKTX’s TA Score has 5 bullish TA indicator(s).
- EDIT’s TA Score: 3 bullish, 6 bearish.
- NKTX’s TA Score: 5 bullish, 4 bearish.
Price Growth
EDIT (@Biotechnology) experienced а -12.50% price change this week, while NKTX (@Biotechnology) price change was -14.45% for the same time period.
The average weekly price growth across all stocks in the @Biotechnology industry was -0.49%. For the same industry, the average monthly price growth was -6.84%, and the average quarterly price growth was -13.86%.
Reported Earning Dates
EDIT is expected to report earnings on Feb 25, 2027.
NKTX is expected to report earnings on Mar 25, 2027.
Industries' Descriptions
@Biotechnology (-0.49% weekly)Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.
Advertisement
NKTX and
Correlation & Price change
A.I.dvisor indicates that over the last year, NKTX has been loosely correlated with CRSP. These tickers have moved in lockstep 49% of the time. This A.I.-generated data suggests there is some statistical probability that if NKTX jumps, then CRSP could also see price increases.
| Ticker / NAME | Correlation To NKTX | 1D Price Change % | ||
|---|---|---|---|---|
| NKTX | 100% | +9.63% | ||
| CRSP - NKTX | 49% Loosely correlated | +1.33% | ||
| EDIT - NKTX | 47% Loosely correlated | -4.99% | ||
| PROK - NKTX | 45% Loosely correlated | +1.80% | ||
| VIR - NKTX | 45% Loosely correlated | -0.15% | ||
| RNAC - NKTX | 44% Loosely correlated | -0.15% | ||
More | ||||